伊达萨努特林和纳维托克拉克斯在T细胞急性淋巴细胞白血病中诱导协同的细胞死亡
Kimberly B Johansson1,2, Megan S Zimmerman3, Iryna V Dmytrenko1
1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
这项研究发现,将idasanutlin与navitoclax结合起来,可以有效地向T细胞急性淋巴细胞白血病 (T-ALL) 细胞. 这种组合疗法通过诱导协同细胞死亡和在临床前模型中改善存活率来治疗T-ALL显著有前途.
科学领域:
- 血液学恶性瘤是什么
- 癌症生物学 癌症生物学
- 分子治疗学分子治疗学
背景情况:
- 在Notch路径中激活突变驱动T细胞急性淋巴细胞白血病 (T-ALL),部分通过c-Myc激活.
- 增加的c-Myc诱导瘤性压力,通过MDM2-p53通路触发细胞亡.
- 大多数T-ALL病例具有上游途径突变,但野生型MDM2和TP53,表明对MDM2抑制的敏感性.
研究的目的:
- 调查MDM2抑制在T-ALL中的有效性.
- 为了评估MDM2抑制剂 (idasanutlin) 与BH3模仿剂的组合,用于T-ALL治疗.
主要方法:
- 治疗T-ALL细胞和患者衍生的异种移植 (PDX) 单独使用伊达桑特林和与BH3模仿剂 (navitoclax,venetoclax) 结合使用.
- 亡诱导,基因表达 (BAX,BBC3) 和体内疗效 (生存) 的评估.
主要成果:
- 单独的伊达萨努特林显示了适度的亡,但上调了BAX和BBC3的亲亡基因.
- 在试验室中,idasanutlin和navitoclax的组合证明了T-ALL PDX线的强有力的协同杀死.
- 组合疗法在临床前T-ALL异种移植模型中显著改善了整体存活率.
结论:
- 伊达萨努特林与纳维托克拉克斯结合,对T-ALL具有显著的协同活性.
- 这种组合疗法需要对T细胞急性淋巴细胞白血病治疗进行进一步的临床研究.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
